Evidence map›Paper›PMID 39164231›Full record

ArticleNature communications2024

RIOK2 transcriptionally regulates TRiC and dyskerin complexes to prevent telomere shortening.

Shrestha Ghosh, Mileena T Nguyen, Ha Eun Choi, Maximilian Stahl, Annemarie Luise Kühn, Sandra Van der Auwera, Hans J Grabe, Henry Völzke, Georg Homuth, Samuel A Myers and 5 more

Abstract read
In one paragraph

Article in Nature communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Multi-omics insights into the mechanisms and prognosis of IPF.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026
    Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Shrestha GhoshDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Shrestha_Ghosh@dfci.harvard.edu.ORCID 0000-0003-1861-8581
Mileena T NguyenDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID 0009-0002-8087-1879
Ha Eun ChoiDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Maximilian StahlDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Annemarie Luise KühnDepartment for Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.ORCID 0000-0002-0158-8286
Sandra Van der AuweraDepartment for Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.ORCID 0000-0002-1757-7768
Hans J GrabeDepartment for Psychiatry and Psychotherapy, University Medicine Greifswald, Greifswald, Germany.
Henry VölzkeInstitute for Community Medicine, University Medicine Greifswald, Greifswald, Germany.
Georg HomuthInterfaculty Institute for Genetics and Functional Genomics, University Medicine Greifswald, Greifswald, Germany.ORCID 0000-0001-6839-0605
Samuel A MyersLa Jolla Institute for Immunology, La Jolla, CA, USA.ORCID 0000-0001-7636-0887
Cory M HogaboamWomen's Guild Lung Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA, USA.ORCID 0000-0003-3366-4850
Imre NothDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, VA, USA.
Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, Weill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-2412-3182
Gregory A PetskoDepartment of Neurology, Ann Romney Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-3668-3694
Laurie H GlimcherDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Laurie_Glimcher@dfci.harvard.edu.ORCID 0000-0002-4971-0404

Funding

1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUG3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2019 to 2019
$977k
Novel agents for idiopathic pulmonary fibrosisR43HL150986 · NHLBI · EPIGEN BIOSCIENCES, INC. · PI HOGABOAM, CORY M, TUCCI, FABIO COHEN · 2020 to 2020
$300k
Multi-faceted Roles of an Atypical Kinase RIOK2 in Erythropoiesis and Myelodyplastic SyndromesR03HL156574 · NHLBI · DANA-FARBER CANCER INST · PI GLIMCHER, LAURIE HOLLIS · 2020 to 2020
$177k
NHLBI NIH HHS R03 HL156574NHLBI NIH HHS UG3 HL145266
6 · The paper itself

Abstract

Telomere shortening is a prominent hallmark of aging and is emerging as a characteristic feature of Myelodysplastic Syndromes (MDS) and Idiopathic Pulmonary Fibrosis (IPF). Optimal telomerase activity prevents progressive shortening of telomeres that triggers DNA damage responses. However, the upstream regulation of telomerase holoenzyme components remains poorly defined. Here, we identify RIOK2, a master regulator of human blood cell development, as a critical transcription factor for telomere maintenance. Mechanistically, loss of RIOK2 or its DNA-binding/transactivation properties downregulates mRNA expression of both TRiC and dyskerin complex subunits that impairs telomerase activity, thereby causing telomere shortening. We further show that RIOK2 expression is diminished in aged individuals and IPF patients, and it strongly correlates with shortened telomeres in MDS patient-derived bone marrow cells. Importantly, ectopic expression of RIOK2 alleviates telomere shortening in IPF patient-derived primary lung fibroblasts. Hence, increasing RIOK2 levels prevents telomere shortening, thus offering therapeutic strategies for telomere biology disorders.

Indexed as

Cell Cycle ProteinsIdiopathic Pulmonary FibrosisNuclear ProteinsTelomeraseTelomere ShorteningFibroblastsGene Expression RegulationHumansLungMyelodysplastic SyndromesTelomereCell Cycle ProteinsDKC1 protein, humanNuclear ProteinsTelomerase

Identifiers

PMID39164231
PMCPMC11335878

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.